Performance evaluation of Espline HTLV-I/II, a newly developed rapid immunochromatographic antibody test for different diagnostic situations
Open Access
- 12 December 2023
- journal article
- research article
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 11 (6) , e0207823
Abstract
Antibody screening tests for human T-cell leukemia virus type 1 (HTLV-1) are performed based on methods such as chemiluminescent enzyme immunoassay (CLEIA), chemiluminescence immunoassay (CLIA), electrochemiluminescence immunoassay, and particle agglutination (PA). Espline HTLV-I/II, a commercially available, easy-to-use, and rapid immunochromatographic antibody test (IC), was developed for situations where expensive instruments and laboratory equipment are not available. In this report, we compared the performance of IC with the above existing tests using diverse samples derived from asymptomatic HTLV-1 carriers and patients with HTLV-1-associated diseases in collaboration with 11 Japanese institutes. We found that IC detected HTLV-1 infection in all samples from HTLV-1-associated diseases, including adult T-cell leukemia, HTLV-1-associated myelopathy, and HTLV-1 uveitis (200/200). The sensitivity of IC compared with CLIA, CLEIA, and PA was 99.2% (363/366), 100% (241/241), and 100% (47/47), respectively, and the specificity was 99.4% (994/1000), 100% (60/60), and 100% (40/40), respectively. The positive and negative predictive values of IC were 99.7% [95% confidence interval (CI): 99.12–99.92] and 99.5% (95% CI: 98.82–99.75), respectively. However, IC had difficulty in correctly judging samples that were diagnosed as seroreactive in other first screening tests but negative by a confirmatory test; for example, of 612 confirmed negative samples that were CLIA seroreactive, 332 samples were IC positive. These results confirmed that IC has sufficient sensitivity and specificity as a screening test for HTLV-1, although, like the other screening tests, it also requires a confirmatory test to determine HTLV-1 infection correctly. IMPORTANCE: The World Health Organization estimated that 5–10 million people are infected with human T-cell leukemia virus type 1 (HTLV-1). This number is likely to be underestimated because reliable endemic data are available for only approximately 1.5 billion people worldwide. The point-of-care test is a powerful tool for the easy and quick detection of infections without the requirement for expensive instruments and laboratory equipment. Espline HTLV-I/II, a newly developed rapid immunochromatographic antibody test that was evaluated in this study, might significantly advance our understanding of the global epidemiology of HTLV-1 infection.Keywords
Funding Information
- Japan Agency for Medical Research and Development (JP22fk0108124j)
- Japan Agency for Medical Research and Development (JP23fk0108671h)
This publication has 32 references indexed in Scilit:
- A New and Frequent Human T-Cell Leukemia Virus Indeterminate Western Blot Pattern: Epidemiological Determinants and PCR Results in Central African InhabitantsJournal of Clinical Microbiology, 2012
- Epidemiological Aspects and World Distribution of HTLV-1 InfectionFrontiers in Microbiology, 2012
- Proviral loads of human T‐lymphotropic virus Type 1 in asymptomatic carriers with different infection routesInternational Journal of Cancer, 2011
- Evaluation of a new third-generation ARCHITECT rHTLV-I/II assay for blood screening and diagnosisDiagnostic Microbiology and Infectious Disease, 2010
- Evaluation of a new, fully automated immunoassay for detection of HTLV‐I and HTLV‐II antibodiesJournal of Medical Virology, 2008
- Human T‐lymphotropic virus type II and neurological diseaseAnnals of Neurology, 2004
- High Rate of HTLV-II Infection in Seropositive IV Drug Abusers in New OrleansScience, 1989
- HTLV-I ASSOCIATED MYELOPATHY, A NEW CLINICAL ENTITYThe Lancet, 1986
- Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease.Proceedings of the National Academy of Sciences, 1982
- Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphomaProceedings of the National Academy of Sciences, 1980